Valproate for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Schwarz, Christian ^a   Volz, Anja ^b   Li, Chunbo ^c   Leucht, Stefan ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TONGJI UNIVERSITY   (China)

Author keywords

Antimanic agents *therapeutic use ; Antipsychotic agents therapeutic use ; Humans; Randomized controlled trials as topic; Schizophrenia *drug therapy ; Valproic acid *therapeutic use

Indexed keywords

ANTIPARKINSON AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CHLORPROTHIXENE; CLONAZEPAM; DIAZEPAM; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; VALPROATE MAGNESIUM; VALPROATE SEMISODIUM; VALPROIC ACID;

ADD ON THERAPY; AGGRESSION; ANXIETY DISORDER; ASTHENIA; ATAXIA; AUTONOMIC DYSFUNCTION; BIOSIS; BODY WEIGHT; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; CONSTIPATION; DELUSIONAL DISORDER; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPEPSIA; EMBASE; EOSINOPHILIA; EXTRAPYRAMIDAL SYNDROME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; INCONTINENCE; LYMPHOCYTOSIS; MEDLINE; MENTAL HEALTH; MONOCYTOSIS; MONOTHERAPY; NAUSEA; PAIN; PSYCINFO; REVIEW; RHINITIS; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 55049120845     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004028.pub3     Document Type: Review

References (56)

1. Casey 2003 {published data only} Casey DE, Daniel DG, Wassef AA, Tracy KA, Wolnlak P, Sommerville W. Effect of divalproex combined with olanzapine or risperidone in patients with acute exercabation of schizophrenia. Neuropsychopharmacology 2003;28:182-92.
2. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatric Services 2004;55(3):290-4. [MEDLINE: 15001730; : EMBASE 2004111171]
3. Jafari M, Jiang P, Casey DE. Adjunctive divalproex sodium lowers cholesterol elevation with olanzapine. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA. 2004. [: APA Conference Abstracts NR634]
4. Dose 1998 {published data only} Dose M. Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991.
5. * Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 1998;31(4):122-5. [MEDLINE: 98425840]
6. Fisk 1987 {published data only} Fisk GG, York SM. The effect of sodiumvalproate on tardive dyskinesia - revisited. British Journal of Psychiatry 1987;150:542-6. [MEDLINE: 86216395]
7. Hesslinger 1999 {published data only} Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of Clinical Psychopharmacology 1999;19(4):310-5. [MEDLINE: 99367069]
8. Wang 2005 {published data only} Wang H. Combination of magnesium valproate and anti-psychotics in aggressive behaviors of schizophrenics. Journal of Clinical Psychosomatic Diseases 2005;11(1):10-1. [: 113903]
9. Wassef 2000 {published data only} Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer WJ 3rd, Rose RM. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. Journal of Clinical Psychopharmacology 2000;20(3):357-61. [MEDLINE: 20289870]
10. Yin 2004 {published data only} Yin X-R, Xie B-Q, Jiang L. A double-blind comparative study of sodium valproate in treating of TD. Journal of Clinical Psychological Medicine 2004;14(2):92-3. [: 113903]
11. Alberti 1999 {published data only} Alberti GG, Garini R, Marzolini M, Beltz J, Greco MI, Maresca G. Efficacy and tolerability of gabapentin (GBP) and valproate (VPA) as an adjunct in the neuroleptic treatment of acute manic syndromes. Journal of the European College of Neuropsychopharmacology 1999;9:210.
12. Centorrino 1994 {published data only} Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. American Journal of Psychiatry 1994;151(1):123-5. [MEDLINE: 94091485]
13. Liang 2004 {published data only} Liang H-X, Du J-Y, Wu Z-J. A study of additive effect of sodium-valproate in the treatment of schizophrenia. Journal of Clinical Psychological Medicine 2004;14(3):151-2. [: 113903]
14. Monfort 1991 {published data only} Monfort JC, Mager C, Thorpe D, Ropert R, Ferrey G, Mentre F, Venaud G, Bourguignon A, Manus A. Valproate-diazepam combination vs chlorpromazine: a double-blind study in schizophrenic and schizophreniform disorders [Valproate-diazépam versus chlorpromazine: étude en double aveugle dans les troubles schizophréniques et schizophréniformes]. Encephale 1991;17(2):101. [MEDLINE: 20289870]
15. Raja 2000 {published data only} Raja M, Azzoni A. Second generation antipsychotics in the emergency care setting. A prospective naturalistic study. General Hospital Psychiatry 2000;22(2):107-14. [MEDLINE: 20283566]
16. Zhu 2005 {published data only} Zhu C, Fu R, Yang Y. Sodium valproate and clonazepam for the treatment of agitated symptoms of patients with schizophrenia: a controlled trial. Medical Journal of the Chinese People's Armed Police Forces 2005;16(12):934-5. [: CAJ MEDI0602]
17. Friis 1983 {published data only} Friis T, Christensen TR, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatrica Scandinavica 1983;67(3):178-87. [MEDLINE: 83227217]
18. Lee 1996 {published data only} Lee MS, Choi BH, Kim SH. Combined use of carbamazepine and valproic acid in negative symptom schizophrenia. 9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands. 1996. [MEDLINE: 83227217]
19. Linnoila 1976 {published data only} Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. British Journal of Psychiatry 1976;129:114-9. [MEDLINE: 77000897]
20. Norrie 2000 {published data only} Norrie PD. Valproate augmentation of antipsychotic therapy. Inter-national Journal of Neuropsychopharmacology 2000;3 (Suppl 1):S173.
21. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
22. Andreasen 1989 Andreasen NC. Scale for the assessment of negative symptoms.. British Journal of Psychiatry 1989;155:53-8.
23. Bagnall 2000 Bagnall A-M, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness (Cochrane review). Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: %3Chtml%3E%3Cbody%3E%3C!- StartFragment-%3E0.1002/14651858.CD001945%3C!-EndFragment-%3E%3C/body%3E%3C/ html%3E]
24. Barnes 1989 Barnes TRE. A rating scale for drug-induced akathisia.. British Journal of Medicine 1989;154:672-6.
25. Begg 1996 Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: the CONSORT statementImproving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-9.
26. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
27. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
28. Cheine 2003 Cheine M, Ahonen J, Wahlbeck K. Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: %3Chtml%3E%3Cbody%3E%3C!-StartFragment-%3E10.1002/14651858.CD000234%3C!- EndFragment-%3E%3C/body%3E%3C/html%3E]
29. Christison 1991 Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin 1991;17:217-45.
30. Citrome 2000 Citrome L, Levine L, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatric Services 2000;51(5):634-8.
31. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
32. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
33. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
34. Gilbody 2000 Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane review). Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD002306]
35. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
36. Guy 1976 Guy U. ECDEU assessment manual for psychopharmacology. Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology. Washington DC: National Institute of Mental Health, 1976.
37. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
38. Higgins 2005 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Cochrane Database of Systematic Reviews. Chichester, UK: Wiley & Sons, 2005, issue 3.
39. Kay 1987 Kay SR, Fiszbein A. The positive and negative symptome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-75.
40. Leucht 2007a Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: %3Chtml%3E%3Cbody%3E%3C!-StartFragment-%3E10.1002/14651858.CD003834. pub2%3C!-EndFragment-%3E%3C/body%3E%3C/html%3E]
41. Leucht 2007b Leucht S, McGrath J, White P, Kissling W. Carbamazapine for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: %3Chtml%3E%3Cbody%3E%3C!-StartFragment-%3E10.1002/14651858. CD001258.pub2%3C!-EndFragment-%3E%3C/body%3E%3C/html%3E]
42. Lorr 1962 Lorr M, McNair DM, Klett CJ, Lasky JJ. Evidence of ten psychotic symptoms. Journal of Consulting Psychology 1962;26:185.
43. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
44. NIMH 1970 National Institute of Mental Health. Clinical Global Impression. In: Guy W, Bonato RR editor(s). Manual for the ECDEU Assessment. 2nd Edition. NIMH, 1970.
45. Overall 1962 Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:790-812.
46. Schooler 1993 Schooler NR, Keith SJ. Clinical research for the treatment of schizophrenia. Psychopharmacology Bulletin 1993;29:431-46.
47. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
48. Simpson 1970 Simpson M, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavia 1970;212:11-9.
49. Srisurapanont 2004 Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: %3Chtml%3E%3Cbody%3E%3C!-StartFragment-%3E10.1002/14651858. CD000967.pub2%3C!-EndFragment-%3E%3C/body%3E%3C/html%3E]
50. Tharyan 2005 Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia (Cochrane Review). Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI:%3Chtml%3E%3Cbody%3E%3C!-StartFragment-%3E10.1002/14651858. CD000076.pub2%3C!-EndFragment-%3E%3C/body%3E%3C/html%3E]
51. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):3-92. [MEDLINE: 10982317]
52. Volz 2007 Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006391]
53. Wahlbeck 1999 Wahlbeck K, Cheine M, Essali MA, Rezk E. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 2. [DOI: %3Chtml%3E%3Cbody%3E%3C!- StartFragment-%3E10.1002/14651858.CD000059%3C!-EndFragment-%3E%3C/body%3E%3C/ html%3E]
54. Wahlbeck 2001 Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Drop-out rates in randomised antipsychotic drug trials. Psychopharmacology 2001;155:230-3.
55. Yudofsky 1986 Yudofsky S, Silver J, Jackson W, Endicott J. The overt aggression scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry 1986;143:35-9.
56. Leucht 2004 Leucht S, White P, McGrath J, Kissling W. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry 2004;65:177-86.